



06-05-03

1631 \$

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ramnarayan *et al.*

Serial No.: 09/709,905

Confirmation No.: 3606; Cust. No. 24961

Filed: November 10, 2000

For: *USE OF COMPUTATIONALLY DERIVED  
PROTEIN STRUCTURES OF GENETIC  
POLYMORPHISMS IN  
PHARMACOGENOMICS FOR DRUG  
DESIGN AND CLINICAL APPLICATIONS*

Art Unit: 1631

Examiner: Brusca, J.

## CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV 338001763 US

Date of Deposit June 3, 2003

I hereby certify that this paper is being deposited  
with the United States Postal "Express Mail Post  
Office to Addressee" Service under 37 C.F.R.  
§1.10 on the date indicated above and addressed  
to:

Commissioner for Patents

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

#32

Jonathan Ong

## TRANSMITTAL LETTER

RECEIVED

Commissioner for Patents  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313

JUN 09 2003

TECH CENTER 1600/2900

Sir:

Transmitted herewith are an Amendment responsive to the Office Action mailed December 3, 2002, with hand-annotated drawings of Figures 4, 6, and 7; copies of formal drawings of Figures 4, 6, 7, and corrected Figures 11 through 11A-32, and a check (\$930) for fee for a 3-month extension of time by a large entity (\$930) for filing in connection with the above-identified application. If a Petition for extension of time is needed, this paper is to be considered such Petition.

## Extension fee for response within the third month:

(X) By a large entity.....\$930.00.

- ☒ The Commissioner is hereby authorized to charge the fee for the extension of time and any other fee that may be due in connection with this and the attached papers or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

06/06/2003 GWARDDEF1 00000026 09709905  
01 FC:1253

930.00 00

Respectfully submitted,  
HELLER EHRMAN WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman, Reg. No. 33,779

Attorney Dkt. No. 24737-1906C  
Address all correspondence to:  
HELLER EHRMAN WHITE & McAULIFFE LLP  
4350 La Jolla Village Drive, 7th Floor  
San Diego, CA 92122-1246  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
EMAIL: sseidman@hewm.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#33/F  
Zita  
6-10-03

Applicant: Ramnarayan *et al.*

Serial No.: 09/709,905

Confirmation No.: 3606; Cust. No. 24961

Filed: November 10, 2000

For: *USE OF COMPUTATIONALLY DERIVED  
PROTEIN STRUCTURES OF GENETIC  
POLYMORPHISMS IN  
PHARMACOGENOMICS FOR DRUG  
DESIGN AND CLINICAL APPLICATIONS*

Art Unit: 1631

Examiner: Brusca, J.

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label Number

EV 338001763 US

Date of Deposit June 3, 2003

I hereby certify that this paper is being deposited with the United States Postal "Express Mail Post Office to Addressee" Service under 37 C.F.R. §1.10 on the date indicated above and addressed to:

Commissioner for Patents  
U.S. Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313

Jonathan Ong

AMENDMENT

RECEIVED

JUN 09 2003

TECH CENTER 1600/2900

Commissioner for Patents

U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313

Dear Sir:

Responsive to the Office Action mailed December 3, 2002, consideration of the following remarks and entry of the following amendment are respectfully requested.

**IN THE SPECIFICATION:**

Please amend the specification as follows (a marked up copy of the amended specification is attached to this Amendment):

**Please replace the paragraph on page 3, lines 22-31, with the following:**

Structural changes that arise as a result of genetic polymorphisms are not of unlimited variety, since 3-D structure impacts upon function. A knowledge of the repertoire of the fine differences among generally similar 3-D structures of particular proteins will permit design of drugs that bind to most polymorphisms, drugs that induce the fewest side-effects, and drugs that are more effective against infectious agents. Knowledge of these structures ultimately will permit